Blood test for KIR3DL2 in Sézary syndrome diagnosis and monitoring
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new blood test that looks for a marker called KIR3DL2 on cancer cells to help diagnose Sézary syndrome, a rare type of skin lymphoma. It may also help doctors see how well treatment is working and if any cancer cells remain after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have health insurance
- You are willing to join the study and have been told about it
- You either have been diagnosed with Sézary syndrome (with red skin covering 80% or more of your body, cancer cells in your blood and skin, and a high level of abnormal cells in your blood at diagnosis) OR you have red, itchy skin covering most of your body that doctors think might be a type of skin lymphoma
- You do not have another active cancer, serious mental illness, or are under legal guardianship
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced blood tests (flow cytometry) to find cancer cells more accurately in people with cutaneous T-cell lymphoma. It could lead to better monitoring of your condition.
This trial tests an oral drug called golidocitinib for people with certain types of T-cell lymphoma. It aims to see if the drug can shrink tumors or improve blood counts.
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.